Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 184

1.

Introduction to the Theme "New Therapeutic Targets".

Insel PA, Amara SG, Blaschke TF, Meyer UA.

Annu Rev Pharmacol Toxicol. 2019 Jan 6;59:15-20. doi: 10.1146/annurev-pharmtox-101018-112717.

PMID:
30625286
2.

Introduction to the Theme "New Approaches for Studying Drug and Toxicant Action: Applications to Drug Discovery and Development".

Insel PA, Amara SG, Blaschke TF, Meyer UA.

Annu Rev Pharmacol Toxicol. 2018 Jan 6;58:33-36. doi: 10.1146/annurev-pharmtox-092617-121952. Epub 2017 Oct 20.

PMID:
29058990
3.

Improving antiretroviral therapy adherence in resource-limited settings at scale: a discussion of interventions and recommendations.

Haberer JE, Sabin L, Amico KR, Orrell C, Galárraga O, Tsai AC, Vreeman RC, Wilson I, Sam-Agudu NA, Blaschke TF, Vrijens B, Mellins CA, Remien RH, Weiser SD, Lowenthal E, Stirratt MJ, Sow PS, Thomas B, Ford N, Mills E, Lester R, Nachega JB, Bwana BM, Ssewamala F, Mbuagbaw L, Munderi P, Geng E, Bangsberg DR.

J Int AIDS Soc. 2017 Mar 22;20(1):21371. doi: 10.7448/IAS.20.1.21371. eCollection 2017.

4.

Digitizing Medicines for Remote Capture of Oral Medication Adherence Using Co-encapsulation.

Browne SH, Peloquin C, Santillo F, Haubrich R, Muttera L, Moser K, Savage GM, Benson CA, Blaschke TF.

Clin Pharmacol Ther. 2018 Mar;103(3):502-510. doi: 10.1002/cpt.760. Epub 2017 Sep 19.

5.

Poor medication adherence in clinical trials: consequences and solutions.

Breckenridge A, Aronson JK, Blaschke TF, Hartman D, Peck CC, Vrijens B.

Nat Rev Drug Discov. 2017 Mar;16(3):149-150. doi: 10.1038/nrd.2017.1. Epub 2017 Feb 3.

PMID:
28154411
6.

Introduction to the Theme "New Methods and Novel Therapeutic Approaches in Pharmacology and Toxicology".

Insel PA, Amara SG, Blaschke TF, Meyer UA.

Annu Rev Pharmacol Toxicol. 2017 Jan 6;57:13-17. doi: 10.1146/annurev-pharmtox-091616-023708. Epub 2016 Oct 12.

PMID:
27732830
7.

Introduction to the Theme "Cancer Pharmacology".

Insel PA, Amara SG, Blaschke TF, Meyer UA.

Annu Rev Pharmacol Toxicol. 2016;56:19-22. doi: 10.1146/annurev-pharmtox-102015-123106. Epub 2015 Nov 9. No abstract available.

PMID:
26551200
8.

Introduction to the theme "Precision medicine and prediction in pharmacology".

Insel PA, Amara SG, Blaschke TF.

Annu Rev Pharmacol Toxicol. 2015;55:11-4. doi: 10.1146/annurev-pharmtox-101714-123102. Epub 2014 Dec 17. No abstract available.

PMID:
25562643
9.

Impact of adherence and anthropometric characteristics on nevirapine pharmacokinetics and exposure among HIV-infected Kenyan children.

Vreeman RC, Nyandiko WM, Liechty EA, Busakhala N, Bartelink IH, Savic RM, Scanlon ML, Ayaya SO, Blaschke TF.

J Acquir Immune Defic Syndr. 2014 Nov 1;67(3):277-86. doi: 10.1097/QAI.0000000000000300.

PMID:
25140906
10.

Integrative continuum: accelerating therapeutic advances in rare autoimmune diseases.

Van Herle K, Behne JM, Van Herle A, Blaschke TF, Smith TJ, Yeaman MR.

Annu Rev Pharmacol Toxicol. 2012;52:523-47. doi: 10.1146/annurev-pharmtox-010611-134628. Review.

PMID:
22235861
11.

Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories.

Blaschke TF, Osterberg L, Vrijens B, Urquhart J.

Annu Rev Pharmacol Toxicol. 2012;52:275-301. doi: 10.1146/annurev-pharmtox-011711-113247. Epub 2011 Sep 19. Review.

PMID:
21942628
12.

Understanding forgiveness: minding and mining the gaps between pharmacokinetics and therapeutics.

Osterberg LG, Urquhart J, Blaschke TF.

Clin Pharmacol Ther. 2010 Oct;88(4):457-9. doi: 10.1038/clpt.2010.171.

PMID:
20856243
13.

Global challenges for clinical pharmacology in the developing world.

Blaschke TF.

Clin Pharmacol Ther. 2009 Jun;85(6):579-81. doi: 10.1038/clpt.2009.54.

PMID:
19451910
14.

Variable adherence to prescribed dosing regimens for protease inhibitors: scope and outcomes.

Blaschke TF.

Curr Opin HIV AIDS. 2008 Nov;3(6):603-7. doi: 10.1097/COH.0b013e32831271c2.

PMID:
19373030
15.

Increased vascular alpha1-adrenergic sensitivity in patients with renal failure: receiving recombinant erythropoeitin.

Abiose AK, Aronow WS, Moreno H Jr, Nair CK, Blaschke TF, Hoffman BB.

Am J Ther. 2007 Sep-Oct;14(5):427-34.

PMID:
17890929
16.

Improving data reliability using a non-compliance detection method versus using pharmacokinetic criteria.

Kshirsagar SA, Blaschke TF, Sheiner LB, Krygowski M, Acosta EP, Verotta D.

J Pharmacokinet Pharmacodyn. 2007 Feb;34(1):35-55. Epub 2006 Sep 27.

PMID:
17004125
17.

Characterization of nelfinavir binding to plasma proteins and the lack of drug displacement interactions.

Motoya T, Thevanayagam LN, Blaschke TF, Au S, Stone JA, Jayewardene AL, Chi J, Aweeka FT.

HIV Med. 2006 Mar;7(2):122-8.

18.

Sex differences in pharmacokinetics and pharmacodynamics.

Gandhi M, Aweeka F, Greenblatt RM, Blaschke TF.

Annu Rev Pharmacol Toxicol. 2004;44:499-523. Review.

PMID:
14744256
19.

Protein binding in antiretroviral therapies.

Boffito M, Back DJ, Blaschke TF, Rowland M, Bertz RJ, Gerber JG, Miller V.

AIDS Res Hum Retroviruses. 2003 Sep;19(9):825-35. Review.

PMID:
14585213
20.

Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors.

Washington CB, Flexner C, Sheiner LB, Rosenkranz SL, Segal Y, Aberg JA, Blaschke TF; AIDS Clinical Trials Group Protocol (ACTG 378) Study Team.

Clin Pharmacol Ther. 2003 May;73(5):406-16.

PMID:
12732841
21.

Model-based analysis of the pharmacokinetic interactions between ritonavir, nelfinavir, and saquinavir after simultaneous and staggered oral administration.

Lu JF, Blaschke TF, Flexner C, Rosenkranz SL, Sheiner LB; AIDS Clinical Trials Group Protocol 378 Investigators.

Drug Metab Dispos. 2002 Dec;30(12):1455-61.

PMID:
12433819
22.

Determination of nelfinavir free drug concentrations in plasma by equilibrium dialysis and liquid chromatography/tandem mass spectrometry: important factors for method optimization.

Herforth C, Stone JA, Jayewardene AL, Blaschke TF, Fang F, Motoya T, Aweeka FT.

Eur J Pharm Sci. 2002 Mar;15(2):185-95.

PMID:
11849916
23.

Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans.

Lesko LJ, Rowland M, Peck CC, Blaschke TF.

Pharm Res. 2000 Nov;17(11):1335-44. Review. No abstract available.

PMID:
11205725
24.

Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans.

Lesko LJ, Rowland M, Peck CC, Blaschke TF, Breimer D, de Jong HJ, Grahnen A, Kuhlmann JJ, Stewart B.

Eur J Pharm Sci. 2000;10(4):iv-xiv. No abstract available.

PMID:
11023342
25.

The disposition of saquinavir in normal and P-glycoprotein deficient mice, rats, and in cultured cells.

Washington CB, Wiltshire HR, Man M, Moy T, Harris SR, Worth E, Weigl P, Liang Z, Hall D, Marriott L, Blaschke TF.

Drug Metab Dispos. 2000 Sep;28(9):1058-62.

PMID:
10950849
26.

Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans.

Lesko LJ, Rowland M, Peck CC, Blaschke TF.

J Clin Pharmacol. 2000 Aug;40(8):803-14.

PMID:
10934664
27.

Nicotine impairs endothelium-dependent dilatation in human veins in vivo.

Chalon S, Moreno H Jr, Benowitz NL, Hoffman BB, Blaschke TF.

Clin Pharmacol Ther. 2000 Apr;67(4):391-7.

PMID:
10801248
28.

Asymmetric dimethylarginine increases mononuclear cell adhesiveness in hypercholesterolemic humans.

Chan JR, Böger RH, Bode-Böger SM, Tangphao O, Tsao PS, Blaschke TF, Cooke JP.

Arterioscler Thromb Vasc Biol. 2000 Apr;20(4):1040-6.

PMID:
10764670
29.

Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system.

Zhang L, Gorset W, Washington CB, Blaschke TF, Kroetz DL, Giacomini KM.

Drug Metab Dispos. 2000 Mar;28(3):329-34.

PMID:
10681378
30.

Vascular reactivity in obstructive sleep apnea syndrome.

Duchna HW, Guilleminault C, Stoohs RA, Faul JL, Moreno H, Hoffman BB, Blaschke TF.

Am J Respir Crit Care Med. 2000 Jan;161(1):187-91.

PMID:
10619819
31.

Heparin-induced vasodilation in human hand veins.

Tangphao O, Chalon S, Moreno HJ Jr, Abiose AK, Blaschke TF, Hoffman BB.

Clin Pharmacol Ther. 1999 Sep;66(3):232-8.

PMID:
10511058
32.

L-arginine and nitric oxide-related compounds in plasma: comparison of normal and arginine-free diets in a 24-h crossover study.

Tangphao O, Chalon S, Coulston AM, Moreno H Jr, Chan JR, Cooke JP, Hoffman BB, Blaschke TF.

Vasc Med. 1999;4(1):27-32.

PMID:
10355867
33.

Pharmacokinetics of intravenous and oral L-arginine in normal volunteers.

Tangphao O, Grossmann M, Chalon S, Hoffman BB, Blaschke TF.

Br J Clin Pharmacol. 1999 Mar;47(3):261-6.

34.

Angiotensin-converting enzyme inhibition improves venous endothelial dysfunction in chronic smokers.

Chalon S, Moreno H Jr, Hoffman BB, Blaschke TF.

Clin Pharmacol Ther. 1999 Mar;65(3):295-303.

PMID:
10096262
35.

Role of nitric oxide in isoprenaline and sodium nitroprusside-induced relaxation in human hand veins.

Chalon S, Tejura B, Moreno H Jr, Urae A, Blaschke TF, Hoffman BB.

Br J Clin Pharmacol. 1999 Jan;47(1):91-8.

36.

Inhibition of angiotensin-converting enzyme in human hand veins.

Chalon S, Bedarida GV, Moreno H Jr, Tejura B, Urae A, Hoffman BB, Blaschke TF.

Clin Pharmacol Ther. 1999 Jan;65(1):58-65.

PMID:
9951431
37.

Pharmacokinetics of L-arginine during chronic administration to patients with hypercholesterolaemia.

Tangphao O, Chalon S, Moreno H Jr, Hoffman BB, Blaschke TF.

Clin Sci (Lond). 1999 Feb;96(2):199-207.

PMID:
9918901
38.

The extent of non-adherence in a large AIDS clinical trial using plasma dideoxynucleoside concentrations as a marker.

Kastrissios H, Suárez JR, Hammer S, Katzenstein D, Blaschke TF.

AIDS. 1998 Dec 3;12(17):2305-11.

PMID:
9863873
39.

Characterizing patterns of drug-taking behavior with a multiple drug regimen in an AIDS clinical trial.

Kastrissios H, Suárez JR, Katzenstein D, Girard P, Sheiner LB, Blaschke TF.

AIDS. 1998 Dec 3;12(17):2295-303.

PMID:
9863872
40.

A Markov mixed effect regression model for drug compliance.

Girard P, Blaschke TF, Kastrissios H, Sheiner LB.

Stat Med. 1998 Oct 30;17(20):2313-33.

PMID:
9819830
41.

Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells.

Washington CB, Duran GE, Man MC, Sikic BI, Blaschke TF.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Nov 1;19(3):203-9.

PMID:
9803961
42.

Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia.

Böger RH, Bode-Böger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, Blaschke TF, Cooke JP.

Circulation. 1998 Nov 3;98(18):1842-7.

PMID:
9799202
43.

Endothelial dysfunction in human hand veins is rapidly reversible after smoking cessation.

Moreno H Jr, Chalon S, Urae A, Tangphao O, Abiose AK, Hoffman BB, Blaschke TF.

Am J Physiol. 1998 Sep;275(3):H1040-5. doi: 10.1152/ajpheart.1998.275.3.H1040.

PMID:
9724311
44.

A semiparametric method for describing noisy population pharmacokinetic data.

Park K, Verotta D, Blaschke TF, Sheiner LB.

J Pharmacokinet Biopharm. 1997 Oct;25(5):615-42.

PMID:
9679225
45.

Exposure-response relationships for saquinavir, zidovudine, and zalcitabine in combination therapy.

Vanhove GF, Gries JM, Verotta D, Sheiner LB, Coombs R, Collier AC, Blaschke TF.

Antimicrob Agents Chemother. 1997 Nov;41(11):2433-8.

46.

Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy.

Vanhove GF, Kastrissios H, Gries JM, Verotta D, Park K, Collier AC, Squires K, Sheiner LB, Blaschke TF.

Antimicrob Agents Chemother. 1997 Nov;41(11):2428-32.

47.

Chloroquine-induced venodilation in human hand veins.

Abiose AK, Grossmann M, Tangphao O, Hoffman BB, Blaschke TF.

Clin Pharmacol Ther. 1997 Jun;61(6):677-83.

PMID:
9209251
48.

Medication compliance as a feature in drug development.

Kastrissios H, Blaschke TF.

Annu Rev Pharmacol Toxicol. 1997;37:451-75. Review.

PMID:
9131261
49.

Patient compliance and drug failure in protease inhibitor monotherapy.

Vanhove GF, Schapiro JM, Winters MA, Merigan TC, Blaschke TF.

JAMA. 1996 Dec 25;276(24):1955-6. No abstract available.

PMID:
8971062
50.

Morphine-induced venodilation in humans.

Grossmann M, Abiose A, Tangphao O, Blaschke TF, Hoffman BB.

Clin Pharmacol Ther. 1996 Nov;60(5):554-60.

PMID:
8941028

Supplemental Content

Loading ...
Support Center